Environmental

AQST's R&D intensity is high versus many specialty pharma peers, which supports lower-waste innovation but also implies a larger laboratory and clinical footprint.

The company discloses no clear peer-leading environmental targets or transition metrics in the provided data, limiting evidence of superior environmental management versus peers.

Capital efficiency appears research-heavy rather than resource-heavy, which can reduce manufacturing emissions exposure relative to commercial-stage peers, but this is not yet structurally advantaged.

No material environmental controversies are indicated in the supplied information, so environmental risk appears manageable rather than a differentiating strength versus peers.

Social

AQST's elevated R&D spend relative to revenue suggests a science-led model that can support patient benefit, but it also increases dependence on specialized talent versus peers.

Stock-based compensation is high versus revenue, which can aid retention in a competitive biotech labor market but may also signal heavier dilution pressure than peers.

The provided data do not show peer-leading patient access, safety, or community metrics, so social positioning remains difficult to distinguish from comparable biotech companies.

No major labor, product-safety, or customer-treatment controversies are evident in the supplied information, which keeps social risk broadly in line with peers.

Governance

Stock-based compensation at 17.3% of revenue is elevated, which can align incentives but also suggests weaker capital discipline than better-governed peers.

The negative debt-to-equity reading likely reflects an equity-heavy balance sheet, which reduces leverage risk but does not by itself demonstrate stronger governance than peers.

High R&D intensity indicates management prioritizes pipeline investment, yet the absence of disclosure on board oversight or capital-allocation controls limits governance confidence versus peers.

No severe governance failures are indicated in the provided data, but the compensation and disclosure profile does not clearly separate AQST from stronger-governed peers.

Overall Score

AQST appears broadly in line with specialty pharma peers on ESG, with science-led operations and manageable controversy risk offset by limited disclosure and elevated compensation intensity.

Score Driver: High R&D Intensity Supports A Credible Operating Model, But Limited ESG Disclosure And Elevated Stock-Based Compensation Prevent A Stronger Peer-Relative Score.